In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent¹ compound that causes cancer cells to attack themselves and die. "This is the first time therapeutic² small molecules³ have been rationally designed from only an RNA sequence -- something many doubted could be done," said Matthew Disney, PhD, an associate professor at TSRI who led the study. "In this case, we have shown that that approach allows for specific and unprecedented⁴ targeting of an RNA that causes cancer."

 

The technique, described in the journal Nature Chemical Biology online ahead of print on February 9, 2014, was dubbed⁵ Inforna.

 

"With our program, we can identify compounds with high specificity," said Sai Pradeep Velagapudi, the first author of the study and a graduate student working in the Disney lab. "In the future, we hope we can design drug candidates for other cancers or for any pathological RNA."

 

In Search of New Approaches

 

In their research program, Disney and his team has been developing approaches to understand the binding⁶ of drugs to RNA folds. In particular, the lab is interested in manipulating microRNAs.

 

Discovered only in the 1990s, microRNAs are short molecules that work within virtually all animal and plant cells. Typically each one functions as a "dimmer switch（变光开关）" for one or more genes⁷; it binds⁸ to the transcripts⁹ of those genes and effectively keeps them from being translated into proteins. In this way microRNAs can regulate a wide variety of cellular¹⁰ processes.

 

Some microRNAs have been associated with diseases. MiR-96 microRNA, for example, is thought to promote cancer by discouraging a process called apoptosis or programmed cell death that can rid the body of cells that begin to grow out of control.

 

As part of its long-term program, the Disney lab developed computational approaches that can mine information against such genome sequences and all cellular RNAs with the goal of identifying drugs that target such disease-associated RNAs while leaving others unaffected.

 

"In recent years we've seen an explosion of information about the many roles of RNA in biology and medicine," said Peter Preusch, PhD, of the National Institute of Health's National Institute of General Medical Sciences, which partially¹¹ funded the research. "This new work is another example of how Dr. Disney is pioneering the use of small molecules to manipulate disease-causing RNAs, which have been underexplored as potential drug targets."

点击收听单词发音